What is Fab'entech?
Fab'entech specializes in the development and production of emergency treatments designed to combat bioterrorism threats and emerging infectious diseases. The company's proprietary FabShield technology platform is central to its operations, enabling the production of highly purified polyclonal antibody fragments. These fragments are engineered to specifically recognize and neutralize a wide array of viruses and toxins, positioning Fab'entech as a key player in providing rapid and effective medical countermeasures for public health emergencies and potential pandemics.
How much funding has Fab'entech raised?
Fab'entech has raised a total of $6.8M across 1 funding round:
Unspecified
$6.8M
Unspecified (2014): $6.8M with participation from Auriga Partners, Rhu00f4ne-Alpes Cru00e9ation, and Sigma Gestion
Key Investors in Fab'entech
Auriga Partners
Auriga Partners is a venture capital firm likely focused on investing in innovative companies, potentially within the technology or life sciences sectors, given its domain.
Rhône-Alpes Création
Rhône-Alpes Création is a French venture capital firm that supports small and medium-sized businesses, likely with a regional focus, investing in companies with growth potential.
Sigma Gestion
Sigma Gestion is an investment management company that facilitates investment in French small and medium businesses, offering various funds to support local enterprises and provide investors with potential returns.
What's next for Fab'entech?
The company's recent major strategic investment, within the context of its enterprise-level funding, suggests Fab'entech is likely in a scaling or late-stage development phase. This capital infusion is expected to accelerate the advancement of its pipeline, which includes comprehensive solutions targeting lethal biological viruses and toxins. Future strategic initiatives will likely focus on expanding manufacturing capabilities, securing regulatory approvals, and establishing robust distribution channels to ensure timely deployment of its life-saving technologies during critical public health events.
See full Fab'entech company page
